Fda Stance On Bpc 157 BPC 157: The Real Reason Why It's Not FDA Approved Stracuzzi Wellness BPC 157: Experimental Peptide Creates Risk for Athletes The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives FDA Peptide Update: Category 2 Removals Explained